Teva (ADR)
Combines global generics scale with innovative neuroscience and immunology medicines.
Something off on this page? Send us feedback.
Profile
Combines global generics with innovative neuroscience and immunology medicines, biosimilars, and pharmacy brands across the United States, Europe, and International Markets. Revenue comes through high-volume medicine sales and branded products, with performance tied to regulatory approvals, pricing and reimbursement, manufacturing compliance, and patent outcomes.
Combines a global generics platform with innovative medicines, biosimilars, over-the-counter products, active ingredients, contract manufacturing, and drug out-licensing. Operations are organized across the United States, Europe, and International Markets.
Sells high-volume generics through pharmacy chains, distributors, wholesalers, health funds, and insurers, while commercializing AUSTEDO, AJOVY, UZEDY, and COPAXONE for neurological conditions. A large manufacturing and regulatory network supports broad product access, while focused development prioritizes neuroscience and immunology.
Execution depends on regulatory approvals, manufacturing compliance, reimbursement and pricing systems, patent and exclusivity outcomes, supply continuity, and commercial performance of newer medicines. Opioid-settlement supply and payment obligations and competition-law resolutions remain operating commitments.
Company facts
Key statistics
Year to date +17.7% · Average volume (30d) 5.5M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 12, 2026 | Barclays | Reiterate | Overweight | $40 | $42 |
| Jul 28, 2026 | Piper Sandler | Reiterate | Overweight | $42 | $44 |
| May 6, 2026 | Barclays | Reiterate | Overweight | $38 | $40 |
| Apr 30, 2026 | Piper Sandler | Reiterate | Overweight | $41 | $42 |
| Apr 30, 2026 | UBS | Reiterate | Buy | $28 | $42 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026Q2 FY26 | $0.08 | $0.02 | −75.0% | $4.02B | $4.14B | +3.0% | +2.02% |
| Apr 29, 2026Q1 FY26 | $0.50 | $0.53 | +6.0% | $3.79B | $3.98B | +5.1% | −0.88% |
| Jan 28, 2026Q4 FY25 | $0.65 | $0.96 | +47.7% | $4.32B | $4.71B | +9.1% | −0.42% |
| Nov 5, 2025Q3 FY25 | $0.68 | $0.78 | +14.7% | $4.45B | $4.48B | +0.6% | −0.57% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.89B | $4.18B | $4.48B | $4.71B | $3.98B | $4.14B | |
| Gross profit | $1.88B | $2.10B | $2.30B | $2.66B | $1.97B | $2.15B | |
| Operating income | $519.0M | $455.0M | $882.0M | $300.0M | $652.0M | $149.0M | |
| Net income | $214.0M | $282.0M | $433.0M | $480.0M | $369.0M | −$576.0M | |
| Diluted EPS | $0.18 | $0.24 | $0.37 | $0.41 | $0.31 | −$0.49 | |
| Gross margin | 48.2% | 50.3% | 51.4% | 56.4% | 49.5% | 52.0% | |
| Operating margin | 13.3% | 10.9% | 19.7% | 6.4% | 16.4% | 3.6% |
Fiscal years (4-quarter sums)FY21 $15.88B · FY22 $14.93B · FY23 $15.85B · FY24 $16.54B · FY25 $17.26B
Revenue by product · Q1 FY26
Revenue by geography · Q1 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $3.66B · Total debt $16.87B · Total assets $39.86B · Shareholders' equity $7.76B
Dividends
No dividends on record.
Ownership
Shares outstanding 1.16B · Float 1.16B · 100.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 63.89M | 5.49% | 13F | Aug 7, 2026 |
| Harel Insurance Investments & Financial Services Ltd. | 48.14M | 4.13% | 13F | Jul 29, 2026 |
| Phoenix Holdings Ltd. | 42.93M | 3.69% | 13F | Aug 11, 2026 |
| WCM Investment Management, LLC | 41.32M | 3.55% | 13F | Aug 13, 2026 |
| Clal Insurance Enterprises Holdings Ltd | 40.60M | 3.49% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 21, 2026 | Amir Weiss | officer: Chief Accounting Officer | −9,445 | $37.62 |
| Aug 21, 2026 | Ronit Satchi-Fainaro | director | −415 | $37.25 |
| Aug 17, 2026 | Evan Lippman | officer: EVP, Business Development | −18,600 | $36.57 |
| Aug 5, 2026 | Tal Zvi Zaks | director | −17 | $34.87 |
| Aug 3, 2026 | Eric A. Hughes | officer: See "Remarks" | −25,578 | $34.88 |
Peers
- Viatris
Global generic medicines across the same major regions
- Dr. Reddy's Laboratories (ADR)
Generics and biosimilars spanning major international markets
- Amneal Pharmaceuticals
U.S. complex generics, injectables, and biosimilars
- Neurocrine Biosciences
INGREZZA directly challenges AUSTEDO in movement disorders
- Eli Lilly
Emgality challenges AJOVY in migraine prevention
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Teva (ADR) | $36.30 | −0.36% | $42.44B | 60.7 | 12.9 | 2.5 | −0.8% |
| Viatris | $16.30 | −0.23% | $19.03B | — | 6.4 | 1.3 | +4.9% |
| Dr. Reddy's Laboratories (ADR) | $12.18 | 0.00% | $10.15B | 29.2 | 32.5 | 3.0 | −16.2% |
| Amneal Pharmaceuticals | $17.54 | 0.00% | $5.60B | 36.0 | 16.9 | 1.8 | +9.9% |
| Neurocrine Biosciences | $154.94 | +0.57% | $15.49B | 22.6 | 16.9 | 4.6 | +39.5% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Median | 32.6 | 16.9 | 3.0 | +9.9% |